MX2016013039A - Glucolipidos y composiciones farmaceuticas de los mismos para usarse en terapia. - Google Patents
Glucolipidos y composiciones farmaceuticas de los mismos para usarse en terapia.Info
- Publication number
- MX2016013039A MX2016013039A MX2016013039A MX2016013039A MX2016013039A MX 2016013039 A MX2016013039 A MX 2016013039A MX 2016013039 A MX2016013039 A MX 2016013039A MX 2016013039 A MX2016013039 A MX 2016013039A MX 2016013039 A MX2016013039 A MX 2016013039A
- Authority
- MX
- Mexico
- Prior art keywords
- group
- derivative
- alkyl
- alkenyl
- alkynyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000000304 alkynyl group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000003342 alkenyl group Chemical group 0.000 abstract 4
- 150000002431 hydrogen Chemical class 0.000 abstract 4
- 125000006686 (C1-C24) alkyl group Chemical group 0.000 abstract 3
- 125000005647 linker group Chemical group 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000000837 carbohydrate group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C07H15/06—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical being a hydroxyalkyl group esterified by a fatty acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se proporciona un compuesto de fórmula I: R1-L1-C(A) (A')-CH2-L2-R2 o una sal farmacéuticamente aceptable del mismo, para usarse en medicina, por ejemplo en el tratamiento de una enfermedad o condición que se selecciona del grupo que comprende cáncer, trastornos de espectro autista, enfermedad de Alzheimer, enfermedad de Parkinson, Corea de Hungtington, agotamiento muscular e infección viral, en donde: R1 se selecciona de un grupo carbohidrato o un derivado del mismo, hidrógeno, un alquilo de 1 a 24 átomos de carbono o un derivado de un grupo alquilo de 1 a 24 átomos de carbono, un alquenilo de 2 a 24 átomos de carbono o un derivado de un grupo alquenilo de 2 a 24 átomos de carbono, y un grupo alquinilo de 2 a 24 átomos de carbono o un derivado de un grupo alquinilo de 2 a 24 átomos de carbono; L1 es un grupo enlazante; L2 es un grupo enlazante; R2 se selecciona de hidrógeno, un alquilo de 1 a 24 átomos de carbono o un derivado de un grupo alquilo de 1 a 24 átomos de carbono, un alquenilo de 2 a 24 átomos de carbono o un derivado de un grupo alquenilo de 2 a 24 átomos de carbono, y un grupo alquinilo de 2 a 24 átomos de carbono o un derivado de un grupo alquinilo de 2 a 24 átomos de carbono; A se selecciona de hidrógeno y un grupo alquilo de 1 a 6 átomos de carbono: A' se selecciona de hidrógeno, un grupo alquilo de 3 a 6 átomos de carbono y L3-R3, en donde L3 es un grupo enlazante; y R3 se selecciona de hidrógeno, un alquilo de 1 a 24 átomos de carbono o un derivado de un grupo alquilo de 1 a 24 átomos de carbono, un alquenilo de 2 a 24 átomos de carbono o un derivado de un grupo alquenilo de 2 a 24 átomos de carbono, y un grupo alquinilo de 2 a 24 átomos de carbono o un derivado de un grupo alquinilo de 2 a 24 átomos de carbono, y en donde, si A' no es L3-R3, entonces R2 es un alquilo de 10 a 24 átomos de carbono o un derivado de un grupo alquilo de 10 a 24 átomos de carbono, un alquenilo de 10 a 24 átomos de carbono o un derivado de un grupo alquenilo de 10 a 24 átomos de carbono o un grupo alquinilo de 10 a 24 átomos de carbono o un derivado de un grupo alquinilo de 10 a 24 átomos de carbono; y en donde, si A' es L3-R3, entonces uno o ambos de R2 y R3 son un alquilo de 10 a 24 átomos de carbono o un derivado de un grupo alquilo de 10 a 24 átomos de carbono, un alquenilo de 10 a 24 átomos de carbono o un derivado de un grupo alquenilo de 10 a 24 átomos de carbono o un grupo alquinilo de 10 a 24 átomos de carbono o un derivado de un grupo alquinilo de 10 a 24 átomos de carbono.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1406172.5A GB201406172D0 (en) | 2014-04-04 | 2014-04-04 | Therapy and pharmaceutical composition |
| PCT/GB2015/051068 WO2015150839A1 (en) | 2014-04-04 | 2015-04-07 | Glycolipids and pharmaceutical compositions thereof for use in therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016013039A true MX2016013039A (es) | 2017-04-27 |
| MX392452B MX392452B (es) | 2025-03-24 |
Family
ID=50776888
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016013039A MX392452B (es) | 2014-04-04 | 2015-04-07 | Glucolipidos y composiciones farmaceuticas de los mismos para usarse en terapia. |
| MX2022006003A MX2022006003A (es) | 2014-04-04 | 2016-10-04 | Glucolipidos y composiciones farmaceuticas de los mismos para usarse en terapia. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006003A MX2022006003A (es) | 2014-04-04 | 2016-10-04 | Glucolipidos y composiciones farmaceuticas de los mismos para usarse en terapia. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10428102B2 (es) |
| EP (2) | EP4285998A3 (es) |
| CN (2) | CN114685414A (es) |
| AU (3) | AU2015242363C1 (es) |
| CA (2) | CA2980885C (es) |
| DK (1) | DK3129057T3 (es) |
| ES (1) | ES2958492T3 (es) |
| GB (1) | GB201406172D0 (es) |
| MX (2) | MX392452B (es) |
| PL (1) | PL3129057T3 (es) |
| WO (1) | WO2015150839A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201406172D0 (en) | 2014-04-04 | 2014-05-21 | Univ Nottingham | Therapy and pharmaceutical composition |
| US20210085742A1 (en) * | 2017-07-28 | 2021-03-25 | The University Of Nottingham | Fruit extract and uses thereof |
| SG11202007005UA (en) * | 2018-01-23 | 2020-08-28 | Academia Sinica | Use of crassocephalum rabens extract in the treatment of breast cancer |
| GB201903873D0 (en) * | 2019-03-21 | 2019-05-08 | Univ Nottingham | Enhanced transfection |
| GB202203181D0 (en) * | 2022-03-08 | 2022-04-20 | Aceae Nutra Ltd | Inhibitors of elF4A |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2668930B1 (fr) * | 1990-11-09 | 1995-02-17 | Oreal | Composition cosmetique, pharmaceutique ou alimentaire comportant une dispersion aqueuse de vesicules lipidiques. |
| GB9819384D0 (en) * | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
| JP2006117582A (ja) | 2004-10-21 | 2006-05-11 | Fancl Corp | インターロイキン４産生抑制剤とその利用 |
| PL1831159T3 (pl) * | 2004-12-21 | 2010-06-30 | Hoffmann La Roche | Pochodne tetraliny i indanu oraz ich zastosowania |
| TW200800306A (en) * | 2005-09-12 | 2008-01-01 | Wyeth Corp | Sustained-release formulation and uses thereof |
| US7547455B2 (en) * | 2006-09-20 | 2009-06-16 | Academia Sinica | Cancer and inflammatory disorder treatment |
| WO2010048955A1 (en) * | 2008-10-30 | 2010-05-06 | Hyben Vital Licens Aps | Composition comprising a glycoside of a mono- or diacyiglycerol compound and an oil rich in n-3 polyunsaturated fatty acids, a method of producing the composition and use of the composition |
| WO2013152299A2 (en) | 2012-04-06 | 2013-10-10 | University Of North Carolina At Chapel Hill | Inhibitors of eif4a and derivatives of pateamine a with antiviral activity and use |
| GB201406172D0 (en) | 2014-04-04 | 2014-05-21 | Univ Nottingham | Therapy and pharmaceutical composition |
| US9649078B2 (en) | 2015-07-28 | 2017-05-16 | Dental Imaging Technologies Corporation | Hybrid X-ray system with detachable radiation shield |
-
2014
- 2014-04-04 GB GBGB1406172.5A patent/GB201406172D0/en not_active Ceased
-
2015
- 2015-04-07 DK DK15717051.5T patent/DK3129057T3/da active
- 2015-04-07 PL PL15717051.5T patent/PL3129057T3/pl unknown
- 2015-04-07 CN CN202210339323.8A patent/CN114685414A/zh active Pending
- 2015-04-07 CA CA2980885A patent/CA2980885C/en active Active
- 2015-04-07 EP EP23182534.0A patent/EP4285998A3/en active Pending
- 2015-04-07 CN CN201580030017.4A patent/CN106413753B/zh active Active
- 2015-04-07 EP EP15717051.5A patent/EP3129057B1/en active Active
- 2015-04-07 US US15/301,264 patent/US10428102B2/en active Active
- 2015-04-07 CA CA3209430A patent/CA3209430A1/en active Pending
- 2015-04-07 WO PCT/GB2015/051068 patent/WO2015150839A1/en not_active Ceased
- 2015-04-07 AU AU2015242363A patent/AU2015242363C1/en active Active
- 2015-04-07 MX MX2016013039A patent/MX392452B/es unknown
- 2015-04-07 ES ES15717051T patent/ES2958492T3/es active Active
-
2016
- 2016-10-04 MX MX2022006003A patent/MX2022006003A/es unknown
-
2019
- 2019-07-25 US US16/522,216 patent/US11248016B2/en active Active
-
2020
- 2020-04-02 AU AU2020202332A patent/AU2020202332B9/en active Active
-
2022
- 2022-06-01 AU AU2022203774A patent/AU2022203774A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020202332B2 (en) | 2022-03-17 |
| PL3129057T3 (pl) | 2023-12-18 |
| AU2015242363A1 (en) | 2016-11-03 |
| EP3129057A1 (en) | 2017-02-15 |
| AU2022203774A1 (en) | 2022-06-23 |
| DK3129057T3 (da) | 2023-10-02 |
| MX2022006003A (es) | 2022-06-22 |
| GB201406172D0 (en) | 2014-05-21 |
| CA2980885C (en) | 2023-10-03 |
| US20190382433A1 (en) | 2019-12-19 |
| CA3209430A1 (en) | 2015-10-08 |
| WO2015150839A1 (en) | 2015-10-08 |
| EP4285998A2 (en) | 2023-12-06 |
| ES2958492T3 (es) | 2024-02-09 |
| MX392452B (es) | 2025-03-24 |
| CA2980885A1 (en) | 2015-10-08 |
| CN106413753A (zh) | 2017-02-15 |
| AU2020202332B9 (en) | 2022-04-07 |
| CN114685414A (zh) | 2022-07-01 |
| AU2020202332A1 (en) | 2020-04-23 |
| CN106413753B (zh) | 2022-04-12 |
| AU2015242363C1 (en) | 2022-09-22 |
| US11248016B2 (en) | 2022-02-15 |
| US20170275323A1 (en) | 2017-09-28 |
| EP3129057B1 (en) | 2023-07-05 |
| AU2015242363B2 (en) | 2020-01-02 |
| EP4285998A3 (en) | 2024-02-14 |
| US10428102B2 (en) | 2019-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122542T1 (el) | Νεα παραγωγα υδροξυεστερα, μια διεργασια για την παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα | |
| CY1118572T1 (el) | Παραγωγο κυκλοαλκανιου | |
| CL2019001077A1 (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer. | |
| CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
| CY1122601T1 (el) | Αναστολεις gsk3 και μεθοδοι χρησης αυτων | |
| MX2022010520A (es) | Macrociclos peptidicos contra acinetobacter baumannii. | |
| CY1123627T1 (el) | Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
| AR094964A1 (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON LA FOSFOINOSITIDA 3-CINASA d (PI3Kd) | |
| NZ768368A (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| MX381041B (es) | Compuesto cíclico tipo cumarina como inhibidor de mek y su uso. | |
| MX380122B (es) | Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas. | |
| MX2017007748A (es) | Compuestos de heteroarilo anulares fusionados y su uso como inhibidores del receptor de la tirocina cinasa (trk). | |
| CR20160523A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| NZ725008A (en) | Compounds for treating spinal muscular atrophy | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| SV2018005663A (es) | Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso en el tratamiento del cancer | |
| CY1123494T1 (el) | Enωσeiς etepoapyλo-kapboξamiδioy ως anaσtoλeiς thς ripk2 | |
| MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
| UY31885A (es) | Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. | |
| UY36145A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| MX2022006003A (es) | Glucolipidos y composiciones farmaceuticas de los mismos para usarse en terapia. | |
| MX389786B (es) | Derivados de 4-metil 7-{[5-heterociclilpirazina-2-il]amino}1,2- dihidro-1,6-naftiridina-5-ona como compuestos inhibidores de cdk4/6 y el uso de los mismos para el tratamiento de cáncer. | |
| CY1122172T1 (el) | Τροποποιητες θειαζολης των a3 υποδοχεων αδενοσινης | |
| PH12018500469A1 (en) | Sulfonamide compounds as voltage-gated sodium channel modulators | |
| PH12016501645A1 (en) | Aminopyrazolone derivative |